Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma
Latest Information Update: 13 May 2022
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Neuroendocrine carcinoma
- Focus Therapeutic Use
- Acronyms Pembro NEC
- 12 Jun 2019 Status changed from active, no longer recruiting to discontinued.
- 29 Mar 2019 Status changed from recruiting to active, no longer recruiting.
- 04 Dec 2017 Status changed from not yet recruiting to recruiting.